CD44 and cancer: In particular, for the therapy of AML, which requires greater cancer cell specificity, in pioneer studies, CAR T cells targeting antigens CD33, CD44, and CD123 have been developed (Jin et al., 2006; Jin et al., 2009; Walter et al., 2012).